Landmark 210 · Trial in people
N-DOSE nicotinamide riboside dose-finding
Will tell us which dose raises brain NAD most reliably. It cannot show slowing. It finished in April 2025 and no result has been found.
In short
An 81-person dose-finding trial of up to 3,000 mg a day of nicotinamide riboside finished in April 2025, but no result has been located.
- What it is
- Trial in people
- Outcome
- Result due Dec 2026
- When
- 2023–2025
- Size
- 81 people · Phase 2
- Approach
- Help cells clean up
- Research lane
- Mitochondria & energy
- Trial registry
- NCT05589766
- Last checked
- 22 Oct 2026
The research record
This is the project's file for this landmark, as written and checked. Sources are listed at the end; anything not yet confirmed is marked "Not yet verified".
Who
Haukeland University Hospital (sponsor), with the University of Bergen.
What is being tested
Whether higher doses raise brain NAD more reliably than 1,000 mg, the dose in NADPARK (landmark 209), which gave variable rises. Phase 2, placebo-controlled, 12 weeks, 81 people enrolled. Arms: placebo; 1,000 mg daily; or escalation from 1,000 to 2,000 to 3,000 mg at four-week steps.
What would count as success
The primary measure is the change in the brain NAD/ATP ratio by 31P magnetic resonance spectroscopy. A clear dose response would define the dose for any further trial. It cannot show slowing of disease and comes after NOPARK's failure (landmark 172).
Status
Completed (primary completion 22 April 2025; record last updated 8 July 2025). No results are posted on the registry, although more than a year has passed since completion, and searches on 19 and 22 Oct 2026 found no paper, preprint or talk. The expected date of December 2026 is a guess, not a sponsor date; the record is unchanged since 8 July 2025.
Sources
- ClinicalTrials.gov NCT05589766 (read via API)
- Not yet verified: any publication or presentation of results (none found, 22 Oct 2026); a sponsor timeline.
How it connects
Built on
- builds on NADPARK Phase 1 · 2022
Led to
None recorded.